(A) qPCR analysis of Pepck, G6pc, and G6pt expression in fed and fasted AAV-Ren– and AAV-shSLU7–infected mice. *P < 0.05 vs. AAV-Ren. (B and C) Hepatic glucose production after (B) pyruvate challenge and (C) glucagon challenge in AAV-Ren– and AAV-shSLU7–infected mice. *P < 0.05 vs. AAV-shSLU7. (D and E) PLC/PRF/5 and HepG2 cells were transfected with siGL or siSLU7. 48 hours later, cells were treated with 10 μM forskolin (FK) for 4 hours, prior to analysis of PEPCK and/or NR4A2 expression. (D) Representative Western blots of PEPCK, SLU7, and ACTIN control. (E) qPCR analysis of PEPCK, NR4A2, and ACTIN control. (F) ChIP assays using control (IgG) or anti-SLU7 antibodies in siGL- or siSLU7-transfected PLC/PRF/5 cells analyzing PEPCK and NR4A2 proximal promoters. (G) ChIP assays of PEPCK and NR4A2 promoters in siGL- and siSLU7-transfected PLC/PRF/5 cells. 48 hours after transfection, cells were treated with 10 μM forskolin for 30 minutes, then subjected to ChIP with anti-CBP and anti–RNA-Pol II antibodies. (H) SLU7 coimmunoprecipitated with P-CREB (arrow), CBP, and RNA-Pol II in PLC/PRF/5 cells. Lysates were immunoprecipitated with anti SLU7 antibodies or preimmune IgG. Representative Western blots of 3 experiments are shown.